ZBH ZIMMER BIOMET HOLDINGS INC.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Zimmer Biomet Holdings, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of Indiana on behalf of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ZBH) (“Zimmer” or the “Company”) securities during the period between September 7, 2016 and October 31, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until January 31, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Zimmer securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that supply chain problems led to a decrease in order fulfillment rates, most notably within Zimmer’s knee and hip portfolios and the Company would not achieve its revenues and profit forecast.

According to the complaint, following an October 31, 2016 press release and conference call disclosing that sales weakness stemming from a change in the supply chain infrastructure, which led to shortfalls in the availability of implants and instrument sets during the quarter, the value of Zimmer shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Zimmer securities purchased on or after September 7, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

EN
17/12/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZIMMER BIOMET HOLDINGS INC.

Zimmer Biomet Holdings, Inc.: Update to credit analysis

Our credit view of this issuer reflects its healthy EBITDA margin and strong free cash flow generation, constrained by its pricing pressure from competition.

Moody's Ratings affirms Zimmer Biomet's Baa2 senior unsecured rating; ...

Moody's Ratings (Moody's) affirmed the senior unsecured ratings of Zimmer Biomet Holdings, Inc. ("Zimmer Biomet") at Baa2. The outlook is stable. The ratings affirmation reflects solid operating performance due to strong demand and operational improvements that have contributed to solid organic gr...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Zimmer Biomet Holdings, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 March 2025 in which we reassessed the appropriateness of the ratings in the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch